Pure Global AI
NCT06365619Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
University of UtahPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
Ipilimumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Utah
Location
Salt Lake City, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2024
End date
Aug 01, 2029
Enrollment
25 participants
Primary outcome

Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery.

Summary

The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and
 nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1
 therapy.
 
 Participants will receive 2 cycles of treatment prior to their standard of care surgery.
 After surgery participants will receive standard of care adjuvant therapy and be followed for
 response.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06365619
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06365619 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Utah and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.